Monopar Therapeutics (MNPR) vs Valneva (VALN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Monopar Therapeutics (MNPR) has outperformed Valneva (VALN) over the past year, losing 15.0% versus a loss of 44.9%. Over five years, MNPR leads with a +241.3% price change compared with -79.1% for VALN. Monopar Therapeutics is the larger company by market cap ($563.7 million vs $539.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MNPR | VALN |
|---|---|---|
| Share price | $83.98 | $5.69 |
| Market cap | $563.69M | $539.55M |
| 1-day change | +0.24% | -3.07% |
| YTD return | +28.30% | -33.45% |
| 1-year return | -14.96% | -44.88% |
| 5-year return | +241.26% | -79.07% |
| Forward P/E | — | 4.78 |
| EPS (TTM) | $-2.20 | $-2.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $124.82 | $12.18 |
| 52-week low | $50.07 | $4.75 |
| Distance from 52-week high | -32.72% | -53.28% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +54.70% | +115.29% |
| Average volume | 215.52K | 78.15K |
| Shares outstanding | 6.71M | 94.82M |
| Employees | 22 | 620 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MNPR has outperformed VALN by 29.9 percentage points over the past year.
About Monopar Therapeutics
MNPR stock →Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
About Valneva
VALN stock →Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 620 employees
MNPR vs VALN FAQ
Which is bigger, Monopar Therapeutics or Valneva?
Monopar Therapeutics (MNPR) is larger, with a market capitalization of $563.69M compared with $539.55M for Valneva (VALN).
Which stock has performed better over the past year, MNPR or VALN?
MNPR returned -14.96% over the past 12 months, compared with -44.88% for VALN (price return, excluding dividends). Past performance does not predict future results.
Are Monopar Therapeutics and Valneva in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Monopar Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Valneva.